A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

05 Jul 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
05 Jul 2023 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2025.
30 Nov 2022 According to an AstraZeneca media release, results from this trial will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight